Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 14/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1146893 | 0.92 | GCK (0.54) | GCKKCNH2 | |
| SCHEMBL2902043 | 0.90 | GCK (0.52) | GCKKCNH2MEN1GAAHTT | |
| SCHEMBL4779901 | 0.90 | GCK (0.52) | GCKKCNH2MEN1GAAHTT | |
| SCHEMBL2175887 | 0.86 | GCK (0.68) | GCKKCNH2 | |
| SCHEMBL4779278 | 0.83 | GCK (0.79) | GCKKCNH2 | |
| SCHEMBL2654104 | 0.83 | GCK (0.79) | GCKKCNH2 | |
| SCHEMBL2654767 | 0.83 | GCK (0.79) | GCKKCNH2 | |
| SCHEMBL2660054 | 0.83 | GCK (0.60) | GCKKCNH2 | |
| SCHEMBL12858867 | 0.83 | GCK (0.53) | GCKKCNH2 | |
| SCHEMBL13891563 | 0.83 | GCK (0.53) | GCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756076-B1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2010-08-11 | — | — | EP | disclosed |
| EP-1756076-B1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2010-08-11 | — | — | EP | disclosed |
| US-7745475-B2 | Such as 3-[(1S)-2-hydroxy-1-methylethoxy]-5-[4-(methylsulfonyl)phenoxy]-N-1,3-thiazol-2-ylbenzamide; glucokinases (Glk) | ASTRAZENECA AB (SE) | 2010-06-29 | — | — | US | disclosed |
| US-7745475-B2 | Such as 3-[(1S)-2-hydroxy-1-methylethoxy]-5-[4-(methylsulfonyl)phenoxy]-N-1,3-thiazol-2-ylbenzamide; glucokinases (Glk) | ASTRAZENECA AB (SE) | 2010-06-29 | — | — | US | disclosed |
| US-7745475-B2 | Such as 3-[(1S)-2-hydroxy-1-methylethoxy]-5-[4-(methylsulfonyl)phenoxy]-N-1,3-thiazol-2-ylbenzamide; glucokinases (Glk) | ASTRAZENECA AB (SE) | 2010-06-29 | — | — | US | disclosed |
| US-20090253676-A1 | Heteroaryl Benzamide Derivatives for Use as GLK Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253676-A1 | Heteroaryl Benzamide Derivatives for Use as GLK Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253676-A1 | Heteroaryl Benzamide Derivatives for Use as GLK Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2009-10-08 | — | — | US | disclosed |
| EP-1992623-A1 | Heteroaryl benzamide derivative for use as GLK activator in the treatment of diabetes | Astra Zeneca AB (SE) | 2008-11-19 | — | — | EP | disclosed |
| EP-1992623-A1 | Heteroaryl benzamide derivative for use as GLK activator in the treatment of diabetes | Astra Zeneca AB (SE) | 2008-11-19 | — | — | EP | disclosed |
| US-20080015203-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015203-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015203-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015203-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | GRK4, GRK5, GRK2 | GCK 9/4885KCNH2 1439/4885MEN1 4029/4885 |
| US-20090253676-A1 | Heteroaryl Benzamide Derivatives for Use as GLK Activators in the Treatment of Diabetes | GRK4, GRK5, GRK2 | GCK 9/4885KCNH2 1406/4885MEN1 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.